Association of IL28B rs12979860 and rs8099917 Gene Polymorphisms with Response to Combination Therapy of Sofosbuvir and Daclatasvir in HCV-Infected Patients from the Khyber Pakhtunkhwa Population

Abstract

Objective: The aim of the study is to analyze if there is are any polymorphisms in IL28B rs12979860 and rs8099917.

Methodology: This is a descriptive study of an emerging phenomenon. Therefore all patients who are diagnosed with chronic Hepatitis C and found resistant to sofosbuvir and Daclatasvir by PCR after at least 12 weeks of initiating treatment and fulfilling our inclusion criteria were recruited in group 1. All those patients who responded to therapy and had negative PCR at 12 weeks were recruited in group 2. Peripheral blood was taken from the patients and kept in ETDA plastic tubes for analysis of IL28B genomic DNA extraction by PCR. The PCR products were then sequenced and analyzed.

Results: No polymorphism was seen in rs12979860. Polymorphism was seen. In rs8099917 however it was not significant

Conclusion: IL28B significantly impacts the immune response to HCV and modulates the interaction of genetic variations with host and viral factors, ultimately influencing treatment outcomes.